Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I trial of a tablet formulation of rociletinib (CO 1686) in Japanese subjects

Trial Profile

A phase I trial of a tablet formulation of rociletinib (CO 1686) in Japanese subjects

Phase of Trial: Phase I

Latest Information Update: 05 May 2016

At a glance

  • Drugs Rociletinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 05 May 2016 According to Clovis Oncology media release, company was notified that it could anticipate receiving a Complete Response Letter (CRL) for the rociletinib NDA on or before the PDUFA date of June 28, 2016 but the FDA issued a CRL stating that the application is not ready for approval. Hence, company has terminated enrollment in all ongoing studies.
    • 05 May 2016 Status changed from active, no longer recruiting to discontinued, as reported by Clovis Oncology media release.
    • 06 May 2015 Status changed from recruiting to active, no longer recruiting, according to a Clovis Oncology media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top